Luke Thorstenson Appointed Director of Business Development for Orgenesis Inc.
Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities in Baltimore.
Vered Caplan, CEO of Orgenesis, stated, “We were thrilled to be able to bring in Luke as we build out the next phase of our operations in the USA. His vast experience in cell and gene therapy, as well as local knowledge of Johns Hopkins University, will be essential as we continue to expand our capabilities in the USA and worldwide.”
Luke has worked in the area of cell and gene therapy for just over 10 years, starting with Adjuvant Partners, a boutique advisory firm focused on cell and gene therapy and helped launch the Alliance for Regenerative Medicine. He also worked for Hitachi Chemical in their Regenerative Medicine Business Sector (formerly known as PCT) as a Market Strategy Analyst. He most recently served as Director of Corporate Partnerships at Johns Hopkins University and as Lead Advisor for Market Research and Strategy at Cell One Partners, an advisory firm focused on cell and gene therapy development leading to commercialization.
“I joined Orgenesis because I not only believe wholeheartedly in the field of cell and gene therapy, but I believe it should be available to everyone. Recently approved cell and gene therapies have clearly demonstrated the transformational nature for this new pillar of treatment, but it comes at a cost not accessible for most of the world,” said Luke Thorstenson. “Orgenesis is developing innovative technologies based around a decentralized model for R&D and manufacturing that is unparalleled. One of the main goals, if not the main goal, of Orgenesis, is to bring the cost of these life-altering treatments down to a level that would allow for global access, that resonated with me.”
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.
Latest posts by BioBuzz Media (see all)
- Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B - September 14, 2021
- Ariel Gruswitz, JD, Joins Facility Logix as Associate Director - September 14, 2021
- USP launches an Office of Organizational Culture, Equity and Inclusion Excellence headed by Chief Equity Officer and Senior Advisor Debra Joy Pérez, Ph.D. - September 13, 2021
- Boyds Opens US Office in Philadephia Area - September 13, 2021
- AbbVie and Rockville’s REGENXBIO Announce Eye Care Collaboration - September 13, 2021